-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112

Benzinga·08/10/2026 17:45:24
Listen to the news
Truist Securities analyst Srikripa Devarakonda maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $106 to $112.